IGF-1 LR3
IGF-1 LR3 is a lab-made, longer-lasting version of insulin-like growth factor 1, the hormone that carries growth signals from the liver to muscle, bone and other tissue. Its evidence base is preclinical, with no published human trials of IGF-1 LR3 itself.
At a glance
- Peptide
- subcutaneous, intramuscular
- Not yet audited here; the reference library calls it emerging
- 40 mcg per Peptide Dosing Protocols. See the source
How much to draw
Full calculator →Opened on 40 mcg, the figure Peptide Dosing Protocols reports for IGF-1 LR3. A reported amount, not a recommendation. Change any number to match the vial in your hand. How to reconstitute a vial.
What sources report
These are figures published elsewhere, reproduced with their source. Peppersite does not recommend an amount for IGF-1 LR3 or for anything else, and nothing below has been checked against the study it came from.
| Amount | Frequency | Route | Reported by |
|---|---|---|---|
| Standard: 40 mcg/day · Low: 20 mcg/day · High: 100 mcg/day | Once daily4 weeks · 4 weeks on, 4 weeks off | Subcutaneous (SubQ) or intramuscular (IM) injection | Peptide Dosing ProtocolsWhat it saysHideHalf-life: 20-30 hours. Standard dosing is 40 mcg/day. |
- Once daily4 weeks · 4 weeks on, 4 weeks off
- Subcutaneous (SubQ) or intramuscular (IM) injection
- Peptide Dosing Protocols
What it saysHide
Half-life: 20-30 hours. Standard dosing is 40 mcg/day.
- reconstituted in 2 mL of bacteriostatic water (500 mcg/mL)
We have not published an audit on IGF-1 LR3. Everything below is reference material, not our own reading of the literature, treat it as a starting point for questions, not as a grade.
How it is thought to work
It carries the same growth signal as natural IGF-1, but stays free and active far longer because the proteins that normally capture IGF-1 bind it poorly. Researchers link this to two structural changes, an arginine in place of glutamic acid at position 3 and a 13-amino-acid extension on the front, giving an 83-amino-acid chain and a half-life of roughly 20-30 hours, with signalling that is mitogenic, meaning it drives cell division, and anti-apoptotic, meaning it blocks cell death. It also lowers blood sugar, which is the basis of its main short-term safety concern. There are no published human efficacy or long-term safety studies of IGF-1 LR3 itself.
IGF-1 LR3 is engineered to carry growth signals from the liver to muscle, bone, and other tissues for a much longer period of time without being captured by proteins that limit IGF-1 activity. Structural changes in the peptide reduce its affinity for IGF binding proteins and extend its half-life to roughly 20-30 hours. [Source: Peptide Dosing Protocols]
Reported side effects
Seen in studies: the closest human dataset is the Increlex programme of native rhIGF-1 in 71 children. Low blood sugar was reported in 30 of 71 subjects (42%), mostly mild or moderate, with five severe cases needing assistance and four involving seizures or loss of consciousness, and rates were highest in the first month. Enlarged tonsils were reported in roughly 15%, raised pressure inside the skull in 3 of the 71, and rapid growth in kidney and spleen length in some patients. Lipohypertrophy at injection sites is also listed.
Reported by users: mild swelling, joint stiffness and headaches, usually dose-related and easing when the dose is reduced or the cycle stops, plus irritation, redness and bruising at injection sites, and progressive abdominal distension with sustained high exposure.
Not ruled out: IGF-1 signalling drives cell division and blocks cell death. In one tumour-bearing rat model, IGF-1 LR3 increased tumour growth, and population studies link higher circulating IGF-1 to the risk of certain cancers. Organ-growth changes are believed to be largely irreversible.
Who should avoid it
People with active or past cancer, or a strong family history of it: IGF-1 signalling drives cell division and blocks cell death, the Increlex label contraindicates use with active or suspected tumours, and population studies link higher circulating IGF-1 to the risk of certain cancers.
People with type 1 or type 2 diabetes or other glucose problems: it lowers blood sugar, so adding it to insulin or to impaired glucose handling can produce unpredictable, severe low blood sugar.
People who are pregnant or breastfeeding: no human safety data exists, and the Increlex label states it should not be used by pregnant women.
Teenagers with open growth plates: there are concerns about disproportionate growth, and mecasermin loses its approved indication once growth plates close, so there is no validated adult indication at all.
People taking insulin or drugs that make the body release insulin: the combination produces additive low blood sugar, and research-community sources flag it as having been linked to hospitalisations.
People with existing heart, kidney, liver or spleen conditions: IGF-1 supports growth in many organs, and Increlex labelling notes rapid increases in kidney and spleen length in some treated patients.
Competitive athletes in tested sport: IGF-1 LR3 is prohibited at all times by WADA and by all major professional sports organisations, and detection methods for it have been published.
What gets monitored
Monitor glucose levels during titration and keep fast-acting carbohydrates available. (reported by Peptide Dosing Protocols)
Common questions
What is IGF-1 LR3?
It is a lab-made, longer-acting version of human insulin-like growth factor 1. Structural changes keep it from being captured by the binding proteins that normally limit IGF-1, so it stays active much longer than the natural hormone.
What is the half-life of IGF-1 LR3?
Roughly 20 to 30 hours. Natural IGF-1 clears much faster, and the difference comes from the structural changes that reduce how tightly IGF binding proteins hold it.
What dose ranges appear in IGF-1 LR3 research protocols?
Reported amounts and schedules for IGF-1 LR3 differ by source, and peppersite does not recommend one. Each reported figure is listed in the dosing rows on this page, next to the source that reports it.
How is IGF-1 LR3 reconstituted?
Sources describe adding bacteriostatic water to the freeze-dried vial and swirling it gently. This is a report of common practice, not a validated procedure.
Open the reconstitution calculator →What is the standard cycle length?
Most research protocols cap on-time at 4 to 6 weeks with at least an equal time off. The reason given is that organ-growth changes are believed to be largely irreversible.
How real is the hypoglycemia risk?
It is the main short-term risk. In the closest human dataset, the Increlex programme with native rhIGF-1, low blood sugar was reported in 42% of subjects, with five severe cases needing assistance. Symptoms include shakiness, sweating, hunger, confusion, dizziness, blurred vision, and at worst seizure or loss of consciousness.
Is IGF-1 LR3 injected subcutaneously or intramuscularly?
Both routes appear in research protocols. Subcutaneous, meaning under the skin, is the most-cited default.
Can IGF-1 LR3 be combined with insulin?
Sources describe the combination as producing additive low blood sugar, and research-community sources flag it as having been linked to hospitalisations. They state there is no protocol justification for pairing the two outside direct clinician supervision.
Sources
- 01Tomas FM, Lemmey AB, Read LC, Ballard FJ. Superior potency of infused IGF-I analogues which bind poorly to IGF-binding proteins is maintained when administered by injection. Journal of Endocrinology (1996)
- 02Tomas FM, Knowles SE, Owens PC, Chandler CS, Francis GL, Read LC, Ballard FJ. Insulin-like growth factor-I (IGF-I) and especially IGF-I variants are anabolic in dexamethasone-treated rats. Biochemical Journal (1992)
- 03Mohan S, Baylink DJ. IGF-binding proteins are multifunctional and act via IGF-dependent and -independent mechanisms. Journal of Endocrinology (2002)
- 04von der Thusen JH, Borensztajn KS, Moimas S, et al. IGF-1 has plaque-stabilizing effects in atherosclerosis by altering vascular smooth muscle cell phenotype. American Journal of Pathology (2011)
- 05Ipsen Biopharmaceuticals. INCRELEX (mecasermin) injection — Highlights of Prescribing Information (2025 revision). FDA accessdata.fda.gov (2025)
- 06European Medicines Agency. Increlex EPAR — Product Information (mecasermin). EMA (2024)
- 07LeRoith D, Roberts CT Jr. The insulin-like growth factor system and cancer. Cancer Letters (2003)
- 08Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nature Reviews Cancer (2008)
- 09Borasio GD, Robberecht W, Leigh PN, et al. A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis. Neurology (1998)
- 10Sorenson EJ, Windbank AJ, Mandrekar JN, et al. Subcutaneous IGF-1 is not beneficial in 2-year ALS trial. Neurology (2008)
- 11Mongongu C, Coudore F, Domergue V, et al. Detection of LongR3-IGF-I, Des(1-3)-IGF-I, and R3-IGF-I using immunopurification and high resolution mass spectrometry for antidoping purposes. Drug Testing and Analysis (2020)
- 12Bailes J, Soloviev M. Insulin-Like Growth Factor-1 (IGF-1) and Its Monitoring in Medical Diagnostic and in Sports. Biomolecules (2021)
- 13Velloso CP. Regulation of muscle mass by growth hormone and IGF-I. British Journal of Pharmacology (2008)
The reference sections on this page come from a compound library we import, not from our own review of the studies. Our own evidence grade appears only where an audit is linked. Research use only; nothing here is medical advice or a protocol.
5-Amino-1MQ (5-amino-1-methylquinolinium) is a small lab-made molecule, not a true peptide, though it is often sold alongside research peptides. It is studied for shrinking fat cells and raising NAD+ levels, and all evidence so far comes from cell and rodent studies, with no published human trial.
BPC-157 (Body Protection Compound 157) is a lab-made chain of 15 amino acids based on a sequence first found in human gastric juice. It is mostly studied in animal models of tendon, ligament, gut and blood-vessel injury, and human evidence is limited to three small pilots.
Cerluten is an oral peptide bioregulator referenced for nervous system support. Its proposed action, tissue-specific peptide bioregulation, is described as theoretical.
CJC-1295 with DAC is a lab-made 30-amino-acid copy of growth hormone-releasing hormone, altered so it attaches to albumin, a protein in the blood. It was studied in early human trials for its effect on growth hormone and IGF-1 levels.
This is a combination research blend sold as one vial: CJC-1295 without DAC, a copy of growth hormone-releasing hormone, plus Ipamorelin, a short peptide that acts on the ghrelin receptor. It is studied as a GHRH and GHRP pairing in growth-hormone research.
Endoluten is a peptide bioregulator taken by mouth, listed in the reference library as pineal support. Its proposed action, tissue-specific peptide bioregulation, is described as theoretical.